Surface Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SURF Nasdaq 8731 https://www.surfaceoncology.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Surface Oncology Inc

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023 - May 4th, 2023 11:00 am
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023 - Apr 18th, 2023 11:00 am
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Mar 16th, 2023 12:00 pm
Surface Oncology Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag - Mar 10th, 2023 11:11 am
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022 - Mar 9th, 2023 12:00 pm
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference - Feb 28th, 2023 9:15 pm
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference - Feb 2nd, 2023 1:00 pm
Shareholders in Surface Oncology (NASDAQ:SURF) are in the red if they invested a year ago - Jan 27th, 2023 11:38 am
TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock? - Jan 12th, 2023 12:06 pm
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology - Jan 9th, 2023 1:00 pm
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors - Jan 5th, 2023 12:30 pm
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting - Nov 7th, 2022 1:00 pm
Analysts Just Made A Significant Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts - Nov 7th, 2022 10:05 am
Surface Oncology Discontinues Work On One Phase 2 Cancer Program, Lays Off 20% Workforce - Nov 2nd, 2022 2:28 pm
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort - Nov 2nd, 2022 10:30 am
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388 - Oct 19th, 2022 11:00 am
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting - Sep 14th, 2022 11:30 am
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference - Sep 7th, 2022 8:30 pm
Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase - Aug 24th, 2022 8:30 pm
Analysts Have Just Cut Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Estimates By 11% - Aug 8th, 2022 10:15 am